These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 24079286)

  • 1. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
    Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
    J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
    Agouridis AP; Tsimihodimos V; Filippatos TD; Dimitriou AA; Tellis CC; Elisaf MS; Mikhailidis DP; Tselepis AD
    Expert Opin Pharmacother; 2011 Dec; 12(17):2605-11. PubMed ID: 21714585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
    Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
    J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
    Keating GM
    Am J Cardiovasc Drugs; 2011 Aug; 11(4):227-47. PubMed ID: 21675801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.
    Muhlestein JB; May HT; Jensen JR; Horne BD; Lanman RB; Lavasani F; Wolfert RL; Pearson RR; Yannicelli HD; Anderson JL
    J Am Coll Cardiol; 2006 Jul; 48(2):396-401. PubMed ID: 16843192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
    Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
    J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study.
    Ansquer JC; Bekaert I; Guy M; Hanefeld M; Simon A;
    Am J Cardiovasc Drugs; 2009; 9(2):91-101. PubMed ID: 19331437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial.
    Harivenkatesh N; David DC; Haribalaji N; Sudhakar MK
    J Cardiovasc Pharmacol Ther; 2014 May; 19(3):296-303. PubMed ID: 24516261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
    Weinstein DL; Williams LA; Carlson DM; Kelly MT; Burns KM; Setze CM; Lele A; Stolzenbach JC
    Clin Ther; 2013 Aug; 35(8):1186-98. PubMed ID: 23891363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients.
    Hamilton SJ; Chew GT; Davis TM; Watts GF
    Clin Sci (Lond); 2010 Feb; 118(10):607-15. PubMed ID: 20047560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome.
    Bays HE; Shah A; Macdonell G; Taggart WV; Gumbiner B
    Metab Syndr Relat Disord; 2011 Apr; 9(2):135-42. PubMed ID: 21117970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
    Nissen SE; Nicholls SJ; Wolski K; Howey DC; McErlean E; Wang MD; Gomez EV; Russo JM
    JAMA; 2007 Mar; 297(12):1362-73. PubMed ID: 17384435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation.
    Dubé MP; Komarow L; Fichtenbaum CJ; Cadden JJ; Overton ET; Hodis HN; Currier JS; Stein JH;
    Clin Infect Dis; 2015 Sep; 61(5):840-9. PubMed ID: 25979307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
    Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
    Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: effect of fenofibrate treatment.
    Chan DC; Wong AT; Yamashita S; Watts GF
    Atherosclerosis; 2012 Apr; 221(2):484-9. PubMed ID: 22341868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.